Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 1
2018 1
2019 1
2020 1
2021 1
2022 8
2023 9
2024 7
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases.
Sadeghi M, Dehnavi S, Asadirad A, Xu S, Majeed M, Jamialahmadi T, Johnston TP, Sahebkar A. Sadeghi M, et al. Inflammopharmacology. 2023 Jun;31(3):1069-1093. doi: 10.1007/s10787-023-01136-w. Epub 2023 Mar 30. Inflammopharmacology. 2023. PMID: 36997729 Free PMC article. Review.
Thus, the current review focuses on the molecular mechanisms associated with curcumin's effects on chemoattractant cytokines, as well as putting into context the many studies that have reported curcumin-mediated regulatory effects on inflammatory conditions in the organs/systems …
Thus, the current review focuses on the molecular mechanisms associated with curcumin's effects on chemoattractant cytokines, as well as put …
Statins and autoimmunity: State-of-the-art.
Dehnavi S, Sohrabi N, Sadeghi M, Lansberg P, Banach M, Al-Rasadi K, Johnston TP, Sahebkar A. Dehnavi S, et al. Pharmacol Ther. 2020 Oct;214:107614. doi: 10.1016/j.pharmthera.2020.107614. Epub 2020 Jun 24. Pharmacol Ther. 2020. PMID: 32592715 Review.
The anti-inflammatory and immune-modulating effects include cell adhesion, migration of antigen presenting cells, and differentiation, as well as activation, of T-cells. In various autoimmune diseases (e.g. rheumatoid arthritis, lupus, and multiple sclerosis), promising re …
The anti-inflammatory and immune-modulating effects include cell adhesion, migration of antigen presenting cells, and differentiation, as we …
Recent advances in improving intranasal allergen-specific immunotherapy; focus on delivery systems and adjuvants.
Sadeghi M, Asadirad A, Koushki K, Keshavarz Shahbaz S, Dehnavi S. Sadeghi M, et al. Int Immunopharmacol. 2022 Dec;113(Pt A):109327. doi: 10.1016/j.intimp.2022.109327. Epub 2022 Oct 17. Int Immunopharmacol. 2022. PMID: 36257257 Review.
Also, multiple microbial agents, including probiotics, mycobacterial and viral components, TLR ligands, and biologic agents, i.e., antibody fragments, recombinant cytokines, vitamin A, and pulsed dendritic cells (DCs), are other platforms that are discussed. ...
Also, multiple microbial agents, including probiotics, mycobacterial and viral components, TLR ligands, and biologic agents, i.e., an …
Mesenchymal Stem Cell-derived Exosome; An Interesting Nanocarrier to Improve Allergen-specific Intranasal Immunotherapy.
Dehnavi S, Dadmanesh M, Hosseini Rouzbahani N, Karimi M, Asadirad A, Gholami M, Ghorban K. Dehnavi S, et al. Iran J Allergy Asthma Immunol. 2023 Dec 28;22(6):561-574. doi: 10.18502/ijaai.v22i6.14645. Iran J Allergy Asthma Immunol. 2023. PMID: 38477953 Free article.
Together with control groups, sensitized Balb/c mice underwent intranasal immunotherapy with Exo-OVA (10 mug OVA per dose) for three consecutive weeks. Serum-specific immunoglobulin E (IgE) levels, transforming growth factor-beta (TGF-beta), interleukin (IL)-4, and interfe …
Together with control groups, sensitized Balb/c mice underwent intranasal immunotherapy with Exo-OVA (10 mug OVA per dose) for three consecu …
Synergistic Wound Healing by Novel Ag@ZIF-8 Nanostructures.
Barjasteh M, Mohsen Dehnavi S, Ahmadi Seyedkhani S, Yahya Rahnamaee S, Golizadeh M. Barjasteh M, et al. Int J Pharm. 2022 Dec 15;629:122339. doi: 10.1016/j.ijpharm.2022.122339. Epub 2022 Oct 28. Int J Pharm. 2022. PMID: 36404467
Animal studies demonstrated excellent healing for the wound treated by CS/BC-25%Ag@ZIF-8 nanocomposite with 91% of wound closure after 14 days of treatment. Hematoxylin and eosin (H&E) staining revealed successful healing and tissue regeneration for the wounds treated …
Animal studies demonstrated excellent healing for the wound treated by CS/BC-25%Ag@ZIF-8 nanocomposite with 91% of wound closure after 14 da …
From Brain Models to Robotic Embodied Cognition: How Does Biological Plausibility Inform Neuromorphic Systems?
Pham MD, D'Angiulli A, Dehnavi MM, Chhabra R. Pham MD, et al. Brain Sci. 2023 Sep 13;13(9):1316. doi: 10.3390/brainsci13091316. Brain Sci. 2023. PMID: 37759917 Free PMC article. Review.
We complete our survey by reviewing different robotic modules that can benefit from neuromorphic hardware, e.g., perception (with a focus on vision), localization, and cognition. We conclude that the tradeoff between symbolic computational power and biological plausibility …
We complete our survey by reviewing different robotic modules that can benefit from neuromorphic hardware, e.g., perception (with a f …
Expression Optimizing of Recombinant Oxalyl-CoA Decarboxylase in Escherichia coli.
Kahaki FA, Dehnavi SM. Kahaki FA, et al. Adv Biomed Res. 2022 Dec 26;11:110. doi: 10.4103/abr.abr_244_21. eCollection 2022. Adv Biomed Res. 2022. PMID: 36798915 Free PMC article.
The vector containing the oxalyl-CoA decarboxylase gene was transformed into E. coli and the expression of the gene was examined on a laboratory scale and fermentor. ...
The vector containing the oxalyl-CoA decarboxylase gene was transformed into E. coli and the expression of the gene was examined on a …
A comprehensive study of mutation and phenotypic heterogeneity of childhood mitochondrial leukodystrophies.
Hosseinpour S, Razmara E, Heidari M, Rezaei Z, Ashrafi MR, Dehnavi AZ, Kameli R, Bereshneh AH, Vahidnezhad H, Azizimalamiri R, Zamani Z, Pak N, Rasulinezhad M, Mohammadi B, Ghabeli H, Ghafouri M, Mohammadi M, Zamani GR, Badv RS, Saket S, Rabbani B, Mahdieh N, Ahani A, Garshasbi M, Tavasoli AR. Hosseinpour S, et al. Brain Dev. 2024 Apr;46(4):167-179. doi: 10.1016/j.braindev.2023.12.003. Epub 2023 Dec 21. Brain Dev. 2024. PMID: 38129218
28 results